nach oben

Pediatric Drugs

Erschienen in:

02.10.2023 | Review Article

Hidradenitis Suppurativa in Children and Adolescents: An Update on Pharmacologic Treatment Options

verfasst von: Nicholas Chiang, Cathryn Sibbald, Rebecca Levy, Irene Lara-Corrales

Erschienen in: Pediatric Drugs | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Hidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory skin condition that manifests as painful, deep-seated, inflamed nodules and abscesses in the axillary, groin, perianal, perineal, and inframammary regions. The associated pain, malodour, and disfigurement contribute to its profound negative impact on psychosocial spheres and overall quality of life in affected individuals. Although the symptoms of HS classically begin in the second or third decade of life, HS affects children and adolescents as well. Despite this, there are limited pediatric data on treatment, which are largely based on expert opinion, extrapolation of efficacy data in adults with HS, and safety information from medication use in other pediatric diseases. On this basis, there exist several pharmacological modalities in the treatment of children and adolescents with HS including topical therapies, systemic therapies, and biologics. The goals of this review article are to: (1) review the efficacy of different pharmacological treatment modalities in children and adolescents with HS, and (2) review the safety and monitoring considerations of the different treatment options in children and adolescents with HS.

Jemec GBE. Hidradenitis suppurativa. N Engl J Med. 2012;366:158–64. https://doi.org/10.1056/NEJMcp1014163.CrossRefPubMed

Ingram J. Hidradenitis suppurativa: Pathogenesis, clinical features, and diagnosis - UpToDate. UpToDate 2022. https://www-uptodate-com.myaccess.library.utoronto.ca/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis?search=hidradenitis&source=search_result&selectedTitle=2~82&usage_type=default&display_rank=2. Accessed 10 March 2023.

Zouboulis Cc, Desai N, Emtestam L, Hunger Re, Ioannides D, Juhász I, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29:619–44. https://doi.org/10.1111/jdv.12966.CrossRefPubMed

Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81:91–101. https://doi.org/10.1016/j.jaad.2019.02.068.CrossRefPubMedPubMedCentral

Mikkelsen PR, Jemec GBE. Hidradenitis suppurativa in children and sdolescents: a review of treatment options. Pediatr Drugs. 2014;16:483–9. https://doi.org/10.1007/s40272-014-0091-3.CrossRef

Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60:539–61. https://doi.org/10.1016/j.jaad.2008.11.911.CrossRefPubMed

Napolitano M, Megna M, Timoshchuk EA, Patruno C, Balato N, Fabbrocini G, et al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clin Cosmet Investig Dermatol. 2017;10:105–15. https://doi.org/10.2147/CCID.S111019.CrossRefPubMedPubMedCentral

Wieczorek M, Walecka I. Hidradenitis suppurative—known and unknown disease. Reumatologia. 2018;56:337–9. https://doi.org/10.5114/reum.2018.80709.CrossRefPubMedPubMedCentral

Cartron A, Driscoll MS. Comorbidities of hidradenitis suppurativa: a review of the literature. Int J Womens Dermatol. 2019;5:330–4. https://doi.org/10.1016/j.ijwd.2019.06.026.CrossRefPubMedPubMedCentral

10.

Chicarilli ZN. Follicular occlusion triad: hidradenitis suppurativa, acne conglobata, and dissecting cellulitis of the scalp. Ann Plast Surg. 1987;18:230–7. https://doi.org/10.1097/00000637-198703000-00009.CrossRefPubMed

11.

Tiri H, Jokelainen J, Timonen M, Tasanen K, Huilaja L. Somatic and psychiatric comorbidities of hidradenitis suppurativa in children and adolescents. J Am Acad Dermatol. 2018;79:514–9. https://doi.org/10.1016/j.jaad.2018.02.067.CrossRefPubMed

12.

Seivright J, Collier E, Grogan T, Hogeling M, Shi VY, Hsiao JL. Physical and psychosocial comorbidities of pediatric hidradenitis suppurativa: a retrospective analysis. Pediatr Dermatol. 2021;38:1132–6. https://doi.org/10.1111/pde.14765.CrossRefPubMedPubMedCentral

13.

Egeberg A, Gislason GH, Hansen PR. Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatol. 2016;152:429–34. https://doi.org/10.1001/jamadermatol.2015.6264.CrossRefPubMed

14.

Choi E, Ooi XT, Chandran NS. Hidradenitis suppurativa in pediatric patients. J Am Acad Dermatol. 2022;86:140–7. https://doi.org/10.1016/j.jaad.2020.08.045.CrossRefPubMed

15.

Liy-Wong C, Kim M, Kirkorian AY, Eichenfield LF, Diaz LZ, Horev A, et al. Hidradenitis suppurativa in the pediatric population. JAMA Dermatol. 2021;157:1–7. https://doi.org/10.1001/jamadermatol.2020.5435.CrossRefPubMedPubMedCentral

16.

Liy-Wong C, Pope E, Lara-Corrales I. Hidradenitis suppurativa in the pediatric population. J Am Acad Dermatol. 2015;73:S36-41. https://doi.org/10.1016/j.jaad.2015.07.051.CrossRefPubMed

17.

Riis PT, Saunte DM, Sigsgaard V, Villani AP, Guillem P, Pascual JC, et al. Clinical characteristics of pediatric hidradenitis suppurativa: a cross-sectional multicenter study of 140 patients. Arch Dermatol Res. 2020;312:715–24. https://doi.org/10.1007/s00403-020-02053-6.CrossRefPubMed

18.

Dessinioti C, Tzanetakou V, Zisimou C, Kontochristopoulos G, Antoniou C. A retrospective study of the characteristics of patients with early-onset compared to adult-onset hidradenitis suppurativa. Int J Dermatol. 2018;57:687–91. https://doi.org/10.1111/ijd.13985.CrossRefPubMed

19.

Deckers IE, van der Zee HH, Boer J, Prens EP. Correlation of early-onset hidradenitis suppurativa with stronger genetic susceptibility and more widespread involvement. J Am Acad Dermatol. 2015;72:485–8. https://doi.org/10.1016/j.jaad.2014.11.017.CrossRefPubMed

20.

Bettoli V, Ricci M, Zauli S, Virgili A. Hidradenitis suppurativa–acne inversa: a relevant dermatosis in paediatric patients. Br J Dermatol. 2015;173:1328–30. https://doi.org/10.1111/bjd.13951.CrossRefPubMed

21.

Offidani A, Molinelli E, Sechi A, Brisigotti V, Campanati A, Raone B, et al. Hidradenitis suppurativa in a prepubertal case series: a call for specific guidelines. J Eur Acad Dermatol Venereol. 2019;33:28–31. https://doi.org/10.1111/jdv.15827.CrossRefPubMed

22.

Kittler NW, Williams JC, Kudlinski MV, Lester J, Hills N, Abuabara K, et al. Evaluation of hidradenitis suppurativa diagnostic criteria in pediatric patients. JAMA Dermatol. 2022;158:1404–8. https://doi.org/10.1001/jamadermatol.2022.4564.CrossRefPubMed

23.

Masson R, Parvathala N, Ma E, Shih T, Atluri S, Sayed CJ, et al. Efficacy of procedural treatments for pediatric hidradenitis suppurativa: a systematic review. Pediatr Dermatol. 2023. https://doi.org/10.1111/pde.15331.CrossRefPubMed

24.

Collier E, Shi VY, Hsiao JL. Management of adolescents with hidradenitis suppurativa. J Dermatol Treat. 2021;32:1035–8. https://doi.org/10.1080/09546634.2020.1716933.CrossRef

25.

De Vere Hunt IJ, Howard E, McPherson T. The impact of chronic skin disease in adolescence and the need for specialist adolescent services. Clin Exp Dermatol. 2020;45:5–9. https://doi.org/10.1111/ced.14021.CrossRefPubMed

26.

Garcovich S, Fania L, Caposiena D, Giovanardi G, Chiricozzi A, De Simone C, et al. Pediatric hidradenitis suppurativa: a cross-sectional study on clinical features and treatment approaches. J Cutan Med Surg. 2022;26:127–34. https://doi.org/10.1177/12034754211039993.CrossRefPubMed

27.

Balgobind A, Finelt N, Strunk A, Garg A. Association between obesity and hidradenitis suppurativa among children and adolescents: a population-based analysis in the United States. J Am Acad Dermatol. 2020;82:502–4. https://doi.org/10.1016/j.jaad.2019.08.034.CrossRefPubMed

28.

Sivanand A, Gulliver WP, Josan CK, Alhusayen R, Fleming PJ. Weight loss and dietary interventions for hidradenitis suppurativa: a systematic review. J Cutan Med Surg. 2020;24:64–72. https://doi.org/10.1177/1203475419874412.CrossRefPubMed

29.

Reichert B, Fernandez Faith E, Harfmann K. Weight counseling in pediatric hidradenitis suppurativa patients. Pediatr Dermatol. 2020;37:480–3. https://doi.org/10.1111/pde.14131.CrossRefPubMed

30.

Wright S, Strunk A, Garg A. New-onset depression among children, adolescents, and adults with hidradenitis suppurativa. J Am Acad Dermatol. 2020;83:1360–6. https://doi.org/10.1016/j.jaad.2020.05.090.CrossRefPubMed

31.

Seivright J, Collier E, Grogan T, Shih T, Hogeling M, Shi VY, et al. Pediatric hidradenitis suppurativa: epidemiology, disease presentation, and treatments. J Dermatol Treat. 2022;33:2391–3. https://doi.org/10.1080/09546634.2021.1937484.CrossRef

32.

Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol. 1983;22:325–8. https://doi.org/10.1111/j.1365-4362.1983.tb02150.x.CrossRefPubMed

33.

Eichenfield LF, Stein Gold L, Kircik LH, Werschler WP, Beer K, Draelos ZD, et al. Triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel for moderate-to-severe acne in children and adolescents: randomized phase 2 study. Pediatr Dermatol. 2023;40:452–9. https://doi.org/10.1111/pde.15283.CrossRefPubMed

34.

Eichenfield LF, Krakowski AC. Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. J Drugs Dermatol. 2012;11:818–24.PubMed

35.

Eichenfield LF, Krakowski AC, Piggott C, Del Rosso J, Baldwin H, Friedlander SF, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics. 2013;131:S163–86. https://doi.org/10.1542/peds.2013-0490B.CrossRefPubMed

36.

Boer J, Jemec GBE. Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa. Clin Exp Dermatol. 2010;35:36–40. https://doi.org/10.1111/j.1365-2230.2009.03377.x.CrossRefPubMed

37.

Pascual JC, Encabo B, de Apodaca RFR, Romero D, Selva J, Jemec GB. Topical 15% resorcinol for hidradenitis suppurativa: an uncontrolled prospective trial with clinical and ultrasonographic follow-up. J Am Acad Dermatol. 2017;77:1175–8. https://doi.org/10.1016/j.jaad.2017.07.008.CrossRefPubMed

38.

Orenstein LAV, Nguyen TV, Damiani G, Sayed C, Jemec GBE, Hamzavi I. Medical and surgical management of hidradenitis suppurativa: a review of international treatment guidelines and implementation in general dermatology practice. Dermatology. 2020;236:393–412. https://doi.org/10.1159/000507323.CrossRefPubMed

39.

Leiphart P, Ma H, Naik HB, Kirby JS. The effect of antimicrobial washes on antibacterial resistance in hidradenitis suppurativa lesions. J Am Acad Dermatol. 2019;80:821–2. https://doi.org/10.1016/j.jaad.2018.10.063.CrossRefPubMed

40.

Frew JW, Hawkes JE, Krueger JG. Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms. Ther Adv Chronic Dis. 2019;10:2040622319830646. https://doi.org/10.1177/2040622319830646.CrossRefPubMedPubMedCentral

41.

Rundle CW, Price KN, Hogeling M, Hsiao JL, Shi VY. Recent advances in hidradenitis suppurativa in pediatrics. Dermatol Online J. 2020. https://doi.org/10.5070/D32612051346.CrossRefPubMed

42.

Brocard A, Knol A-C, Khammari A, Dréno B. Hidradenitis suppurativa and zinc: a new therapeutic approach. Dermatology. 2007;214:325–7. https://doi.org/10.1159/000100883.CrossRefPubMed

43.

Duncan A, Yacoubian C, Watson N, Morrison I. The risk of copper deficiency in patients prescribed zinc supplements. J Clin Pathol. 2015;68:723–5. https://doi.org/10.1136/jclinpath-2014-202837.CrossRefPubMed

44.

Bettoli V, Zauli S, Virgili A. Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: can some factors influence the response to the treatment? G Ital Dermatol E Venereol Organo Uff Soc Ital Dermatol E Sifilogr. 2016;151:216–8.

45.

Bettoli V, Toni G, Odorici G, Forconi R, Corazza M. Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa–acne inversa in patients of paediatric age: a pilot prospective study. Br J Dermatol. 2021;185:216–7. https://doi.org/10.1111/bjd.19867.CrossRefPubMed

46.

Bettoli V, Zauli S, Borghi A, Toni G, Minghetti S, Ricci M, et al. Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 patients. J Eur Acad Dermatol Venereol. 2014;28:125–6. https://doi.org/10.1111/jdv.12127.CrossRefPubMed

47.

Seddon JA, Johnson S, Palmer M, van der Zalm MM, Lopez-Varela E, Hughes J, et al. Multidrug-resistant tuberculosis in children and adolescents: current strategies for prevention and treatment. Expert Rev Respir Med. 2021;15:221–37. https://doi.org/10.1080/17476348.2021.1828069.CrossRefPubMed

48.

Xi Y, Zhang W, Qiao R-J, Tang J. Risk factors for multidrug-resistant tuberculosis: a worldwide systematic review and meta-analysis. PLoS ONE. 2022;17: e0270003. https://doi.org/10.1371/journal.pone.0270003.CrossRefPubMedPubMedCentral

49.

Caposiena Caro RD, Cannizzaro MV, Botti E, Di Raimondo C, Di Matteo E, Gaziano R, et al. Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasound observations. J Am Acad Dermatol. 2019;80:1314–21. https://doi.org/10.1016/j.jaad.2018.11.035.CrossRefPubMed

50.

Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998;39:971–4. https://doi.org/10.1016/s0190-9622(98)70272-5.CrossRefPubMed

51.

Patel K, Leszczynska M, Peña-Robichaux V, Diaz LZ. Caring for pediatric hidradenitis suppurativa patients in the emergency department. Pediatr Emerg Care. 2021;37:312. https://doi.org/10.1097/PEC.0000000000002448.CrossRefPubMed

52.

Lambert RA, Stein SL. Pediatric hidradenitis suppurativa: describing care patterns in the emergency department. Pediatr Dermatol. 2023;40:434–9. https://doi.org/10.1111/pde.15231.CrossRefPubMed

53.

Todd SR, Dahlgren FS, Traeger MS, Beltrán-Aguilar ED, Marianos DW, Hamilton C, et al. No visible dental staining in children treated with doxycycline for suspected rocky mountain spotted fever. J Pediatr. 2015;166:1246–51. https://doi.org/10.1016/j.jpeds.2015.02.015.CrossRefPubMed

54.

Volovitz B, Shkap R, Amir J, Calderon S, Varsano I, Nussinovitch M. Absence of tooth staining with doxycycline treatment in young children. Clin Pediatr (Phila). 2007;46:121–6. https://doi.org/10.1177/0009922806290026.CrossRefPubMed

55.

Yazdanyar S, Boer J, Ingvarsson G, Szepietowski JC, Jemec GBE. Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatol Basel Switz. 2011;222:342–6. https://doi.org/10.1159/000329023.CrossRef

56.

Steyn M, Ayis S, O’Connor J, Lakhan MK, Ferguson F, Shah A, et al. Dapsone therapy for hidradenitis suppurativa: a retrospective review of characteristics and treatment outcomes in a cohort of 122 patients in a tertiary dermatology setting. Br J Dermatol. 2022. https://doi.org/10.1093/bjd/ljac120.CrossRef

57.

Stavola JJ, Noel GJ. Efficacy and safety of dapsone prophylaxis against Pneumocystis carinii pneumonia in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 1993;12:644–7. https://doi.org/10.1097/00006454-199308000-00004.CrossRefPubMed

58.

Meeker ND, Goldsby R, Terrill KR, Delaney KS, Slayton WB. Dapsone therapy for children with immune thrombocytopenic purpura. J Pediatr Hematol Oncol. 2003;25:173.CrossRefPubMed

59.

Kliegman R, Stanton B, St. Geme J, Schor N. Nelson textbook of pediatrics Elsevier eBook on VitalSource. 20th ed. Berlin: Elsevier; 2015.

60.

Join-Lambert O, Coignard-Biehler H, Jais J-P, Delage M, Guet-Revillet H, Poirée S, et al. Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients. J Antimicrob Chemother. 2016;71:513–20. https://doi.org/10.1093/jac/dkv361.CrossRefPubMed

61.

Nicholson C, Ford H, Williams M. The use of intravenous ertapenem in the management of severe hidradenitis suppurativa. J Am Acad Dermatol. 2016;74:AB9. https://doi.org/10.1016/j.jaad.2016.02.036.CrossRef

62.

Arguedas A, Cespedes J, Botet FA, Blumer J, Yogev R, Gesser R, et al. Safety and tolerability of ertapenem versus ceftriaxone in a double-blind study performed in children with complicated urinary tract infection, community-acquired pneumonia or skin and soft-tissue infection. Int J Antimicrob Agents. 2009;33:163–7. https://doi.org/10.1016/j.ijantimicag.2008.08.005.CrossRefPubMed

63.

Karaaslan A, Kadayifci EK, Atici S, Akkoc G, Yakut N, Öcal Demir S, et al. The clinical efficacy and safety of ertapenem for the treatment of complicated urinary tract infections caused by esbl-producing bacteria in children. Int J Nephrol. 2015. https://doi.org/10.1155/2015/595840.CrossRefPubMedPubMedCentral

64.

Zhao R, Long X, Wang J, Zhu J, Liu C, Shang T, et al. Effectiveness of ertapenem for treatment of infections in children: an evidence mapping and meta-analysis. Front Pediatr 2022;10:982179.

65.

Abdel-Rahman SM, Kearns GL, Topelberg S, Jacobs RF, Mistry GC, Majumdar A, et al. Pharmacokinetics and tolerability of single-dose intravenous ertapenem in infants, children and adolescents. Pediatr Infect Dis J. 2010;29:1072–6. https://doi.org/10.1097/INF.0b013e3181e82608.CrossRefPubMedPubMedCentral

66.

Magalhães RF, Rivitti-Machado MC, Duarte GV, Souto R, Nunes DH, Chaves M, et al. Consensus on the treatment of hidradenitis suppurative—Brazilian Society of Dermatology. An Bras Dermatol. 2019;94:7–19. https://doi.org/10.1590/abd1806-4841.20198607.CrossRefPubMedPubMedCentral

67.

Fajgenbaum K, Crouse L, Dong L, Zeng D, Sayed C. Intralesional triamcinolone may not be beneficial for treating acute hidradenitis suppurativa lesions: a double-blind, randomized, placebo-controlled trial. Dermatol Surg. 2020;46:685. https://doi.org/10.1097/DSS.0000000000002112.CrossRefPubMed

68.

Saunte DML, Jemec GBE. Intralesional triamcinolone for hidradenitis suppurativa—how much is needed? Dermatol Surg. 2021;47:1013. https://doi.org/10.1097/DSS.0000000000002753.CrossRefPubMed

69.

Álvarez P, García-Martínez FJ, Poveda I, Pascual JC. Intralesional triamcinolone for fistulous tracts in hidradenitis suppurativa: an uncontrolled prospective trial with clinical and ultrasonographic follow-up. Dermatology. 2020;236:46–51. https://doi.org/10.1159/000499934.CrossRefPubMed

70.

Anderson MD, Zauli S, Bettoli V, Boer J, Jemec GBE. Cyclosporine treatment of severe Hidradenitis suppurative—a case series. J Dermatol Treat. 2016;27:247–50. https://doi.org/10.3109/09546634.2015.1088128.CrossRef

71.

Abu Rached N, Gambichler T, Dietrich JW, Ocker L, Seifert C, Stockfleth E, et al. The role of hormones in hidradenitis suppurativa: a systematic review. Int J Mol Sci. 2022;23:15250. https://doi.org/10.3390/ijms232315250.CrossRefPubMedPubMedCentral

72.

Kraft JN, Searles GE. Hidradenitis suppurativa in 64 female patients: retrospective study comparing oral antibiotics and antiandrogen therapy. J Cutan Med Surg. 2007;11:125–31. https://doi.org/10.2310/7750.2007.00019.CrossRefPubMed

73.

McPhie ML, Bridgman AC, Kirchhof MG. Combination therapies for hidradenitis suppurativa: a retrospective chart review of 31 patients. J Cutan Med Surg. 2019;23:270–6. https://doi.org/10.1177/1203475418823529.CrossRefPubMed

74.

Horissian M, Maczuga S, Barbieri JS, Zaenglein AL. Trends in the prescribing pattern of spironolactone for acne and hidradenitis suppurativa in adolescents. J Am Acad Dermatol. 2022;87:684–6. https://doi.org/10.1016/j.jaad.2021.12.005.CrossRefPubMed

75.

Clark AK, Quinonez RL, Saric S, Sivamani RK. Hormonal therapies for hidradenitis suppurativa: Review. Dermatol Online J. 2017;23:13030/qt6383k0n4.PubMed

76.

Khandalavala BN, Do MV. Finasteride in hidradenitis suppurativa. J Clin Aesthetic Dermatol. 2016;9:44–50.

77.

Randhawa HK, Hamilton J, Pope E. Finasteride for the treatment of hidradenitis suppurativa in children and adolescents. JAMA Dermatol. 2013;149:732–5. https://doi.org/10.1001/jamadermatol.2013.2874.CrossRefPubMed

78.

Mota F, Machado S, Selores M. Hidradenitis suppurativa in children treated with finasteride—a case series. Pediatr Dermatol. 2017;34:578–83. https://doi.org/10.1111/pde.13216.CrossRefPubMed

79.

Irwig MS. Persistent sexual side effects of finasteride: could they be permanent? J Sex Med. 2012;9:2927–32. https://doi.org/10.1111/j.1743-6109.2012.02846.x.CrossRefPubMed

80.

Oliveira-Soares R, André MC, Peres-Correia M. Adverse effects with finasteride 5 mg/day for patterned hair loss in premenopausal women. Int J Trichology. 2018;10:48–50. https://doi.org/10.4103/ijt.ijt_73_15.CrossRefPubMedPubMedCentral

81.

Verdolini R, Clayton N, Smith A, Alwash N, Mannello B. Metformin for the treatment of hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venereol. 2013;27:1101–8. https://doi.org/10.1111/j.1468-3083.2012.04668.x.CrossRefPubMed

82.

Jennings L, Hambly R, Hughes R, Moriarty B, Kirby B. Metformin use in hidradenitis suppurativa. J Dermatol Treat. 2020;31:261–3. https://doi.org/10.1080/09546634.2019.1592100.CrossRef

83.

Soliman A, De Sanctis V, Alaaraj N, Hamed N. The clinical application of metformin in children and adolescents: a short update. Acta Bio Medica Atenei Parm. 2020;91: e2020086. https://doi.org/10.23750/abm.v91i3.10127.CrossRef

84.

Marques P, Limbert C, Oliveira L, Santos MI, Lopes L. Metformin effectiveness and safety in the management of overweight/obese nondiabetic children and adolescents: metabolic benefits of the continuous exposure to metformin at 12 and 24 months. Int J Adolesc Med Health. 2017. https://doi.org/10.1515/ijamh-2015-0110.CrossRef

85.

Srinivasan S, Ambler GR, Baur LA, Garnett SP, Tepsa M, Yap F, et al. Randomized, Controlled trial of metformin for obesity and insulin resistance in children and adolescents: Improvement in body composition and fasting insulin. J Clin Endocrinol Metab. 2006;91:2074–80. https://doi.org/10.1210/jc.2006-0241.CrossRefPubMed

86.

Soria A, Canoui-Poitrine F, Wolkenstein P, Poli F, Gabison G, Pouget F, et al. Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients’ outcome assessment. Dermatol Basel Switz. 2009;218:134–5. https://doi.org/10.1159/000182261.CrossRef

87.

Norris JF, Cunliffe WJ. Failure of treatment of familial widespread hidradenitis suppurativa with isotretinoin. Clin Exp Dermatol. 1986;11:579–83. https://doi.org/10.1111/j.1365-2230.1986.tb00512.x.CrossRefPubMed

88.

Huang CM, Kirchhof MG. A new perspective on isotretinoin treatment of hidradenitis suppurativa: a retrospective chart review of patient outcomes. Dermatology. 2017;233:120–5. https://doi.org/10.1159/000477207.CrossRefPubMed

89.

Stojkovic-Filipovic JM, Gajic-Veljic MD, Nikolic M. Prepubertal onset of hidradenitis suppurativa in a girl: a case report and literature review. Indian J Dermatol Venereol Leprol. 2015;81:294. https://doi.org/10.4103/0378-6323.152741.CrossRefPubMed

90.

Lopes S, Gomes N, Trindade E, Azevedo F, Magina S. Hidradenitis suppurativa in a prepubertal girl. Acta Dermatovenerol Alp Pannonica Adriat. 2019. https://doi.org/10.15570/actaapa.2019.34.CrossRefPubMed

91.

Boer J, Nazary M. Long-term results of acitretin therapy for hidradenitis suppurative. Is acne inversa also a misnomer? Br J Dermatol. 2011;164:170–5. https://doi.org/10.1111/j.1365-2133.2010.10071.x.CrossRefPubMed

92.

Matusiak L, Bieniek A, Szepietowski JC. Acitretin treatment for hidradenitis suppurativa: a prospective series of 17 patients. Br J Dermatol. 2014;171:170–4. https://doi.org/10.1111/bjd.12884.CrossRefPubMed

93.

López-Llunell C, Riera-Martí N, Gamissans M, Romaní J. Dapsone in hidradenitis suppurativa: a case series of 56 patients. Dermatol Ther. 2021;34: e15161. https://doi.org/10.1111/dth.15161.CrossRefPubMed

94.

Meyer E, de Bersaques J, Lambert WE, de Leenheer AP, Kint AH. Skin, adipose tissue and plasma levels of acitretin with rare occurrence of esterified acitretin during long-term treatment. Acta Derm Venereol. 1993;73:113–5. https://doi.org/10.2340/0001555573113115.CrossRefPubMed

95.

Grønhøj Larsen F, Steinkjer B, Jakobsen P, Hjorter A, Brockhoff PB, Nielsen-Kudsk F. Acitretin is converted to etretinate only during concomitant alcohol intake. Br J Dermatol. 2000;143:1164–9. https://doi.org/10.1046/j.1365-2133.2000.03883.x.CrossRefPubMed

96.

Allergan Inc. Soriatane Product Monograph 2018.

97.

Martin-Ezquerra G, Masferrer E, Masferrer-Niubò M, Ferran M, Sánchez-Regaña M, Collgros H, et al. Use of biological treatments in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2015;29:56–60. https://doi.org/10.1111/jdv.12438.CrossRefPubMed

98.

McLenon J, Rogers MAM. The fear of needles: a systematic review and meta-analysis. J Adv Nurs. 2019;75:30–42. https://doi.org/10.1111/jan.13818.CrossRefPubMed

99.

Doyle R, Donaldson A, Philips L, Nelson L, Clark JE, Wen SCH. The impact of a multidisciplinary care package for vaccination in needle phobic children: An observational study. J Paediatr Child Health. 2022;58:1174–80. https://doi.org/10.1111/jpc.15928.CrossRefPubMedPubMedCentral

100.

Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375:422–34. https://doi.org/10.1056/NEJMoa1504370.CrossRefPubMed

101.

Jemec GBE, Okun MM, Forman SB, Gulliver WPF, Prens EP, Mrowietz U, et al. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials. Br J Dermatol. 2019;181:967–75. https://doi.org/10.1111/bjd.17919.CrossRefPubMedPubMedCentral

102.

AbbVie Corporation. Humira Product Monograph 2022.

103.

Nguyen Q-BD, Starling CT, Hebert AA. The use of TNFα inhibitors in treating pediatric skin disorders. Pediatr Drugs. 2020;22:311–9. https://doi.org/10.1007/s40272-020-00394-3.CrossRef

104.

Fougerousse A-C, Reguiai Z, Roussel A, Bécherel P-A. Hidradenitis suppurativa management using tumor necrosis factor inhibitors in patients younger than 18 years: a series of 12 cases. J Am Acad Dermatol. 2020;83:199–201. https://doi.org/10.1016/j.jaad.2020.02.071.CrossRefPubMed

105.

Sachdeva M, Kim P, Mufti A, Maliyar K, Sibbald C, Alavi A. Biologic use in pediatric patients with hidradenitis suppurativa: a systematic review. J Cutan Med Surg. 2022;26:176–80. https://doi.org/10.1177/12034754211049711.CrossRefPubMed

106.

Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62:205–17. https://doi.org/10.1016/j.jaad.2009.06.050.CrossRefPubMed

107.

Cecchin V, Zannin ME, Ferrari D, Pontikaki I, Miserocchi E, Paroli MP, et al. Longterm safety and efficacy of adalimumab and infliximab for uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2018;45:1167–72. https://doi.org/10.3899/jrheum.171006.CrossRefPubMed

108.

Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): Week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. The Lancet. 2023;401:747–61. https://doi.org/10.1016/S0140-6736(23)00022-3.CrossRef

109.

Glatt S, Jemec GBE, Forman S, Sayed C, Schmieder G, Weisman J, et al. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial. JAMA Dermatol. 2021;157:1279–88. https://doi.org/10.1001/jamadermatol.2021.2905.CrossRefPubMed

110.

Martora F, Megna M, Battista T, Potestio L, Annunziata MC, Marasca C, et al. Adalimumab, ustekinumab, and secukinumab in the management of hidradenitis suppurativa: a review of the real-life experience. Clin Cosmet Investig Dermatol. 2023;16:135–48. https://doi.org/10.2147/CCID.S391356.CrossRefPubMedPubMedCentral

111.

Kashetsky N, Mufti A, Alabdulrazzaq S, Lytvyn Y, Sachdeva M, Rahat A, et al. Treatment outcomes of IL-17 inhibitors in hidradenitis suppurativa: a systematic review. J Cutan Med Surg. 2022;26:79–86. https://doi.org/10.1177/12034754211035667.CrossRefPubMed

112.

Lim SYD, Oon HH. Systematic review of immunomodulatory therapies for hidradenitis suppurativa. Biol Targets Ther. 2019;13:53–78. https://doi.org/10.2147/BTT.S199862.CrossRef

113.

Markota Čagalj A, Marinović B, Bukvić MZ. New and emerging targeted therapies for hidradenitis suppurativa. Int J Mol Sci. 2022;23:3753. https://doi.org/10.3390/ijms23073753.CrossRefPubMedPubMedCentral

114.

Fieldhouse KA, Ukaibe S, Crowley EL, Khanna R, O’Toole A, Gooderham MJ. Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors. Drugs Context. 2020;9:2020-2–2021. https://doi.org/10.7573/dic.2020-2-1.CrossRef

115.

Romaní J, Vilarrasa E, Martorell A, Fuertes I, Ciudad C, Molina-Leyva A. Ustekinumab with intravenous infusion: results in hidradenitis suppurativa. Dermatol Basel Switz. 2020;236:21–4. https://doi.org/10.1159/000501075.CrossRef

116.

Blok JL, Li K, Brodmerkel C, Horvátovich P, Jonkman MF, Horváth B. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol. 2016;174:839–46. https://doi.org/10.1111/bjd.14338.CrossRefPubMed

117.

Provini LE, Stellar JJ, Stetzer MN, Nguyen PD, Jen M. Combination hyperbaric oxygen therapy and ustekinumab for severe hidradenitis suppurativa. Pediatr Dermatol. 2019;36:381–3. https://doi.org/10.1111/pde.13775.CrossRefPubMed

118.

Monsalvez V. Hidradenitis suppurativa and ulcerative colitis, difficult treatment to control both pathologies at the same time. Exp Dermatol 2019;28(Supplement 2):21.

119.

Dudink K, Bouwman K, Chen Y, DePrimo SE, Munoz-Elias EJ, Aarts P, et al. Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study. Br J Dermatol. 2023. https://doi.org/10.1093/bjd/ljad010.CrossRefPubMed

120.

Jørgensen AR, Holm JG, Thomsen SF. Guselkumab for hidradenitis suppurativa in a patient with concomitant Crohn’s disease: report and systematic literature review of effectiveness and safety. Clin Case Rep. 2020;8:2874–7. https://doi.org/10.1002/ccr3.3090.CrossRefPubMedPubMedCentral

121.

Kimball AB, Prens EP, Passeron T, Maverakis E, Turchin I, Beeck S, et al. Efficacy and safety of risankizumab for the treatment of hidradenitis suppurativa: A phase 2, randomized, placebo-controlled trial. Dermatol Ther. 2023;13:1099–111. https://doi.org/10.1007/s13555-023-00913-3.CrossRef

122.

Roberts EE, Nowsheen S, Davis DMR, Hand JL, Tollefson MM, Wetter DA. Use of spironolactone to treat acne in adolescent females. Pediatr Dermatol. 2021;38:72–6. https://doi.org/10.1111/pde.14391.CrossRefPubMed

Titel: Hidradenitis Suppurativa in Children and Adolescents: An Update on Pharmacologic Treatment Options
verfasst von: Nicholas Chiang
Cathryn Sibbald
Rebecca Levy
Irene Lara-Corrales
Publikationsdatum: 02.10.2023
Verlag: Springer International Publishing
Erschienen in: Pediatric Drugs / Ausgabe 6/2023
Print ISSN: 1174-5878
Elektronische ISSN: 1179-2019
DOI: https://doi.org/10.1007/s40272-023-00595-6

Neu im Fachgebiet Pädiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

16.05.2024 Arterielle Hypertonie in der Pädiatrie Nachrichten

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Hidradenitis Suppurativa in Children and Adolescents: An Update on Pharmacologic Treatment Options

Abstract

Neu im Fachgebiet Pädiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Update Pädiatrie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2023

Diagnosis and Management of the Systemic Juvenile Idiopathic Arthritis Patient with Emerging Lung Disease

Scope of JAK Inhibitors in Children: Recent Evidence and Way Forward

Respiratory Syncytial Virus Prefusion F Subunit Vaccine: First Approval of a Maternal Vaccine to Protect Infants

Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015)

Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab

The Future of Advanced Therapies for Pediatric Crohn’s Disease

Neu im Fachgebiet Pädiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Update Pädiatrie